1.	Phase III Randomized Study of Prophylactic Topical Sunscreen for the Prevention of Erlotinib-, Cetuximab-, or Other Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rash in Patients With Cancer Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N05C4, N05C4, NCCTG N05C4, NCT00362986
2.	Zalutumumab in Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Zalutumumab, NCT00093041
3.	A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMD 72000-030, NCT00073541
4.	Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: EMD 72000-031, NCT00111839
5.	MATRIX EG (Matuzumab Treatment With ECX in Esophago-Gastric Cancer) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMD 72000-032, NCT00215644
6.	Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EMD 72000-024, NCT00113581